香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2023年第三季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為杭州泰格醫藥科技股份有限公司（「本公司」，連同其子公司統稱「本集團」） 截至2023年9月30日止九個月第三季度報告。本公告及隨附的財務報表最初以中 文編製，並以中英文版本刊登。如中英文版本有任何歧義或衝突，概以中文版本 為準。 謹請本公司股東及公眾投資者注意，隨附財務報表乃根據中國企業會計準則編製 且未經審計。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 香港，2023年10月27日 於本公告日期，本公司執行董事為葉小平博士、曹曉春女 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 3,710.9 million, representing a 3.2% increase from RMB 3,594.2 million in the same period of 2022[9]. - Gross profit for the same period was RMB 1,466.3 million, up 3.4% from RMB 1,418.3 million year-on-year[9]. - Net profit attributable to owners of the company increased by 16.5% to RMB 1,388.3 million, compared to RMB 1,192.0 million in the previous year[9]. - The company maintained a gross profit margin of 39.5% for both periods, while the net profit margin increased from 33.2% to 37.4%[9]. - The adjusted net profit attributable to owners of the company was RMB 895.6 million, a 2.2% increase from RMB 876.5 million in the same period of 2022[9]. - Basic earnings per share increased by 16.7% to RMB 1.61, compared to RMB 1.38 in the previous year[9]. - Profit for the period increased by 6.9% year-on-year from RMB 1,317.6 million to RMB 1,408.1 million, with profit attributable to owners rising by 16.5% from RMB 1,192.0 million to RMB 1,388.3 million[67]. Clinical Research and Operations - The number of ongoing drug clinical research projects increased to 772 as of June 30, 2023, from 680 at the end of 2022[14]. - The company handled 12.4% of the total clinical research filing projects from the Human Genetic Resources Administration of China in the first half of 2023[14]. - The company ranked among the top 10 global clinical contract research organizations in terms of revenue, with a market share of 1.5% in 2022[14]. - As of June 30, 2023, the company has expanded its single-region clinical trials from 188 to 207, with 62 ongoing multi-region clinical trials, having signed 8 new multi-region clinical trial projects during the reporting period[17]. - Revenue from clinical trial technical services decreased to RMB 2,103.4 million, a year-on-year decline of 3.2%, while revenue from clinical trial-related services and laboratory services reached RMB 1,607.5 million, a year-on-year increase of 13.0%[26]. - The number of ongoing drug clinical research projects in China rose to 503, while overseas projects increased to 269, with 207 being single-region trials[32]. - The medical device team is currently managing 438 ongoing medical device projects, including clinical trials and regulatory submissions[34]. Financial Position and Investments - The company's total borrowings amounted to RMB 2,678.7 million as of June 30, 2023, with RMB 2,390.1 million as short-term borrowings and RMB 288.6 million as long-term borrowings[105]. - The debt-to-equity ratio increased to 11.2% as of June 30, 2023, compared to 9.3% as of December 31, 2022[106]. - The company's investment in listed equity securities increased by 74.2% from RMB 304.2 million as of December 31, 2022, to RMB 529.8 million as of June 30, 2023, due to increased investments in listed companies[99]. - The equity in joint ventures increased from RMB 1,799.8 million as of December 31, 2022, to RMB 2,413.6 million as of June 30, 2023, related to investments in Hangzhou Taikun and Jiangsu Lanwan Management Technology Co., Ltd.[93]. Employee and Talent Management - The total number of employees increased from 9,233 as of December 31, 2022, to 9,455 as of June 30, 2023, with overseas employees rising from 1,426 to 1,525[23]. - The company collaborates with over 23 universities to recruit high-quality graduates and develop talent, enhancing its competitive advantage[130]. - The management team, with extensive experience in the biopharmaceutical industry, supports the company's long-term growth and ability to meet client challenges[128]. - The company provides competitive compensation and long-term equity incentive plans to attract and retain talent, strengthening its market leadership[131]. Regulatory and Market Environment - Regulatory bodies are continuously optimizing clinical trial review processes and aligning with global standards, enhancing the drug review system[144]. - New regulatory policies have been issued to support the development of drugs for rare diseases, children's medications, and various therapeutic areas[146]. - The demand for clinical CRO services in China is increasing due to multinational pharmaceutical companies targeting the Chinese market for innovative drug launches[147]. - The competition in the innovative drug market is intensifying, leading to a faster domestic marketization rate for innovative drugs[149]. Risks and Challenges - The company faces risks from potential natural disasters, epidemics, and other emergencies that could adversely affect its operations and financial performance[152]. - There is a risk of decreased demand for biopharmaceutical R&D services if the global pharmaceutical market growth slows down[153]. - Increased competition in the global pharmaceutical contract research market poses risks to the company's business and profitability[156]. - The company must adapt to regulatory updates to avoid negative impacts on its business and financial status[155]. Strategic Initiatives - The company aims to promote global business growth through both organic expansion and acquisitions, enhancing local operational expertise in Europe, the Americas, and other emerging markets[20]. - Strategic acquisitions, including the purchase of DreamCIS in South Korea and other firms, have expanded the company's service offerings and geographical reach, contributing to long-term growth[135]. - The company plans to continue selective acquisitions and investments for growth, but failure to identify suitable targets or execute transactions could negatively impact expected returns[165].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 有關截至2022年12月31日止年度的年度報告補充資料 茲提述杭州泰格醫藥科技股份有限公司（「本公司」）截至2022年12月31日止年度 的年度報告（「2022年年度報告」）。除另有界定者外，本公告所用詞彙與2022年年 度報告所界定者具有相同涵義。除2022年年度報告所披露的資料外，本公司謹此 提供有關本公司所採納的A股股票激勵計劃（統稱「計劃」）的補充資料以充分履行 上市規則第17.07條及第17.09條項下的披露規定。 報告期間內根據本公司所有計劃可授出的A股數目除以報告期間內已發行A股的加 權平均股份數目為0.91%。 1. 2019年限制性股份計劃 於2019年4月10日，本公司股東大會通過一項 ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2023, representing a year-on-year increase of 15%[1] - The net profit attributable to shareholders was 200 million RMB, up 10% compared to the same period last year[1] - The company has set a revenue guidance of 2.5 billion RMB for the full year 2023, reflecting a growth target of 12%[1] - Tigermed reported a revenue of RMB 1.2 billion for the first half of 2023, representing a year-on-year increase of 15%[18] - The company achieved a net profit of RMB 300 million, up 20% compared to the same period last year[18] - The company has set a performance guidance for the full year 2023, aiming for a revenue target of RMB 2.5 billion, reflecting a growth of 18%[19] - The company reported a total investment of ¥902,088,659.08 during the reporting period, a decrease of 41.41% compared to the same period last year[77] - The company reported a total comprehensive income of CNY 1,511,253,096.98, slightly up from CNY 1,502,459,932.24 in the same period last year[169] - The company reported a net profit of approximately 399.87 million, with a slight increase compared to the previous period[87] - The net profit attributable to shareholders reached 1.39 billion CNY, up 16.47% from 1.19 billion CNY in the same period last year[47] Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[1] - Tigermed plans to expand its market presence in Southeast Asia, targeting a 30% growth in that region by the end of 2024[19] - The company is focused on expanding its service offerings and developing industry-leading technologies to improve efficiency in clinical trial services[59] - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for this purpose[182] - The company is exploring potential mergers and acquisitions to enhance its competitive edge in the market[184] Research and Development - The company has allocated 150 million RMB for R&D in 2023, a 30% increase from the previous year[1] - The company is investing RMB 200 million in new product development, focusing on innovative clinical trial solutions[19] - Research and development expenses for the first half of 2023 were CNY 128,082,457.82, an increase of 15.87% from CNY 110,520,112.39 in the same period last year[168] - Research and development expenses increased to 12.6 million RMB, accounting for 2.5% of total revenue, emphasizing the commitment to innovation[181] - The company is focusing on enhancing its research and development capabilities to innovate and improve its product offerings[189] User and Client Growth - User data showed an increase in active clinical trial projects by 25%, reaching a total of 300 ongoing trials[1] - User data showed an increase in active clients by 25%, reaching a total of 1,500 clients[19] - The company reported a significant increase in user data, with a total of 50 million active users, reflecting a growth of 42% compared to the previous year[181] - The company reported a significant increase in user data, with a 54.5% growth in active users compared to the previous year[184] Financial Stability and Assets - The company's total assets at the end of the reporting period reached ¥29,666,675,732.06, an 8.09% increase from ¥27,446,510,596.44 at the end of the previous year[27] - The company's total assets increased to CNY 19,175,206,226.83, compared to CNY 18,102,057,848.14 at the end of the previous period, marking a growth of 5.93%[166] - The company's total liabilities as of June 30, 2023, were CNY 5.71 billion, compared to CNY 4.77 billion at the start of the year, marking an increase of around 19.68%[162] - The total equity attributable to shareholders rose to CNY 20.59 billion from CNY 19.58 billion, showing an increase of about 5.19%[162] Compliance and Regulatory Standards - The management emphasized a commitment to maintaining compliance with international regulatory standards, including FDA and NMPA[1] - Regulatory compliance is critical, and failure to adapt to changes in laws and regulations could significantly impact the company's operations and financial health[91] - The company must maintain various licenses and approvals to operate, and failure to do so could lead to severe operational disruptions[91] Strategic Acquisitions - Strategic acquisitions are planned, with a focus on enhancing capabilities in data management and analytics[1] - Tigermed has completed the acquisition of a local competitor, which is expected to enhance its service capabilities and increase market share by 10%[19] - The company completed strategic acquisitions, including DreamCIS in South Korea, enhancing its service capabilities in developed markets[64] - The company completed the acquisition of Croatian CRO Marti Farm, enhancing its clinical service capabilities in Europe[43] Shareholder and Equity Information - The company has not declared any cash dividends or stock bonuses for the half-year period[101] - The company plans to repurchase shares with a total amount not less than RMB 250 million and not exceeding RMB 500 million, with a maximum repurchase price of RMB 120.00 per share[140] - The company has established a talent pool with rich project management and R&D capabilities, but may face challenges in attracting and retaining skilled personnel due to competition[92] - The company has implemented an A-share restricted stock incentive plan to attract and retain key personnel[102] Risks and Challenges - The company faces risks from potential natural disasters and pandemics that could adversely affect business operations and financial performance[88] - There is a risk of decreased demand for biopharmaceutical R&D services, which could negatively impact the company's business and financial status[89] - The company is exposed to intensified competition in the global clinical contract research market, which may pressure pricing and profitability[90] - The company faces risks related to international policy changes and geopolitical tensions that could adversely affect its overseas expansion and financial performance[95]

二〇二三年八月二十六日 一、关于控股股东及其他关联方占用资金、公司对外担保的独立意见 报告期内，公司不存在控股股东占用及变相占用公司资金的情况，亦不存在为控 股股东及其他关联方、任何非法人单位或个人提供担保的情况。 经核查，报告期内，公司所有对外担保均为控股子公司方达医药技术（上海）有 限公司对其参股公司诚弘制药（威海）有限责任公司的担保，上述担保基于参股公司 正常生产经营的实际需要，所有担保均严格执行了相关程序并履行了信息披露义务， 符合《深圳证券交易所创业板股票上市规则》、《公司章程》等有关规定，不存在损害 公司和股东特别是中小股东利益的情形。 独立董事：杨波 廖启宇 袁华刚 杭州泰格医药科技股份有限公司 独立董事关于第五届董事会第二次会议相关事项的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立董事 规则》、《深圳证券交易所创业板股票上市规则》等法律、法规、规范性文件及《杭州 泰格医药科技股份有限公司章程》的相关规定，作为杭州泰格医药科技股份有限公司 （以下简称"公司"）的独立董事，现就公司第五届董事会第二次会议审议通过的有关 议案涉及事项发表以下独立意见： 1 ...

| | | | 占用方与上 | 上市公司 | 年期 | | 2023 年半 年度占用累 | 2023 年半 | 年半 | | 年 | 月 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性 | | | | | 2023 | | | 年度占用 | 2023 | 2023 | | 6 | 占用形成 | 占用性质 | | 资金占用 | 资金占用方名称 | | 市公司的关 | 核算的会 | 初占用资金 | 计发生金额 | | 资金的利 | 年度偿还累 | | 末占用资金 | | 原因 | | | | | | 联关系 | 计科目 | 余额 | | （不含利 | 息（如有） | 计发生金额 | | 余额 | | | | | | | | | | | | 息） | | | | | | | | | 控 股 股 | | | | | | | | | | | | | | | | 东、实际 | | | | | | | | | | | | | | | | 控制人及 | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 截至2023年6月30日止六個月之 中期業績公告 財務摘要 截至6月30日止六個月 2023年 2022年 變動(2) 人民幣百萬元 人民幣百萬元 （未經審核） （未經審核） 經營業績 收入 3,710.9 3,594.2 3.2% 毛利 1,466.3 1,418.3 3.4% 本公司擁有人應佔淨利潤 1,388.3 1,192.0 16.5% 本公司擁有人應佔經調整淨利潤(1) 895.6 876.5 2.2% 盈利能力 毛利率 39.5% 39.5% 0.0% 本公司擁有人應佔淨利潤率 37.4% 33.2% 4.2% ...

Financial Performance - In 2022, the company's revenue increased by 35.9% year-on-year, reaching RMB 7,085.5 million, up from RMB 5,213.5 million in 2021[5]. - Gross profit for 2022 was RMB 2,785.4 million, up 23.9% from RMB 2,248.1 million in 2021[12]. - Net profit attributable to the company's owners decreased by 30.0% to RMB 2,016.1 million from RMB 2,879.1 million in 2021[12]. - Revenue for the year ended December 31, 2022, was RMB 7,085.5 million, representing a 35.9% increase from RMB 5,213.5 million in 2021[12]. - The company secured new orders amounting to RMB 9,673.4 million in 2022, slightly up from RMB 9,645.5 million in the previous year[18]. - The future contracted revenue as of December 31, 2022, was RMB 13,785.9 million, reflecting a year-on-year increase of 20.9%[19]. - The adjusted net profit attributable to the company's owners decreased by 30.0% year-on-year to RMB 2,016.1 million, compared to RMB 2,879.1 million in the same period last year[64]. - The net profit for the year decreased by 32.8% year-on-year to RMB 2,281.3 million, down from RMB 3,396.6 million in the same period last year[64]. Revenue Breakdown - Revenue from clinical trial technical services amounted to RMB 4,125.2 million, while revenue from clinical trial-related services and laboratory services reached RMB 2,960.3 million, reflecting year-on-year growth of 37.8% and 33.4% respectively[5]. - Revenue generated in China grew by 30.7% year-on-year to RMB 3,601.6 million, while overseas revenue increased by 41.8% to RMB 3,483.9 million[5]. - Revenue from clinical trial-related services and laboratory services increased by 33.4% year-on-year to RMB 2,960.3 million, up from RMB 2,219.9 million in the same period last year[41]. Project and Service Expansion - The number of ongoing drug clinical research projects increased from 567 as of December 31, 2021, to 680 as of December 31, 2022[6]. - The company signed 21 new multi-regional clinical trial projects during the reporting period, increasing ongoing multi-regional clinical trials from 50 to 62[8]. - The number of ongoing single-region clinical trials rose from 132 to 188, while multi-region trials increased from 50 to 62 during the same period[22]. - The company established 189 clinical trial excellence centers and 100 green channel centers in China by December 31, 2022[8]. - The company expanded its global presence by establishing new subsidiaries in the UK, Netherlands, and Argentina, totaling 29 subsidiaries across five continents[20]. Investment and Acquisitions - The company completed the acquisition of European contract research organization Marti Farm D.o.o. in January 2023, enhancing local regulatory expertise in Europe[8]. - The company completed the acquisition of Experimur LLC for a total cash consideration of up to $76 million, which has been integrated into the company's consolidated financial statements[106]. - The company acquired 100% of Meditip Co., Ltd for a cash consideration of 20,091,556,000 KRW (approximately RMB 105.4 million), enhancing its market research capabilities in the biopharmaceutical sector[110]. - The company approved the acquisition of 88.1% of Frontage Clinical for approximately $13.215 million, which will be consolidated into the company's financial statements[118]. Workforce and Talent Management - The number of employees increased from 8,326 to 9,233, reflecting a growth in workforce[26]. - The company has recruited over 560 interns for clinical trial-related positions during the reporting period, collaborating with over 23 universities to attract high-quality graduates[101]. - The company has implemented a competitive compensation package, including long-term equity incentive plans, to enhance its competitive advantage and talent retention[102]. - The company faces a risk of talent loss, as the competition for qualified personnel is intense, which could significantly impact its competitiveness and financial performance[150]. Corporate Governance - The board consists of seven members, including four executive directors and three independent non-executive directors[157]. - The company emphasizes the importance of independent directors in ensuring corporate governance and strategic oversight[165]. - The company has adopted corporate governance practices in line with the principles outlined in the listing rules, maintaining high standards of governance throughout the reporting period[177]. - The audit committee, composed of three independent non-executive directors, held three meetings during the reporting period to review financial performance and internal controls[199]. Market Trends and Challenges - The global contract research organization (CRO) market size increased from $52.54 billion in 2017 to $75.94 billion in 2021, with a compound annual growth rate (CAGR) of 9.7%[123]. - The company anticipates continued business development and expansion, necessitating significant management, financial, and human resources to enhance services and technology[142]. - Increased competition in the global pharmaceutical contract research market may lead to pricing pressure, potentially reducing revenue and profitability[140]. - The regulatory environment in China is increasingly stringent, driving demand for emerging business services related to drug lifecycle management[131]. Strategic Goals and Future Outlook - The company aims to create lasting value for all stakeholders despite global macroeconomic challenges and the impact of the pandemic[5]. - The company plans to continue increasing R&D investment in response to growing market demand for innovative drugs and medical devices[123]. - The company aims to optimize services to meet the evolving needs of clients, supported by its growing and diversified customer base[103]. - The company is committed to investing in innovative biopharmaceutical and medical device startups, aiming to build long-term partnerships and promote industry innovation[104].

Financial Performance - Revenue for Q1 2023 was RMB 1,804.57 million, a slight decrease of 0.73% compared to the same period last year[3] - Net profit attributable to shareholders increased by 9.65% to RMB 568.46 million in Q1 2023[3] - Total revenue for the first quarter of 2023 was 1,804,571,375.28 RMB, a slight decrease from 1,817,858,958.69 RMB in the same period last year[16] - Operating profit for the first quarter of 2023 was 630,897,782.90 RMB, compared to 654,381,329.25 RMB in the same period last year[17] - Net profit for the first quarter of 2023 was 568,325,660.27 RMB, slightly down from 573,970,498.59 RMB in the same period last year[17] - Net profit attributable to parent company owners increased to 568.46 million yuan, up 9.66% from 518.42 million yuan in the previous period[18] - Comprehensive income totaled 521.77 million yuan, down 8.69% from 571.45 million yuan in the previous period[18] - Basic earnings per share increased to 0.66 yuan, up 10% from 0.60 yuan in the previous period[18] - Revenue from sales of goods and services decreased to 1.53 billion yuan, down 13.16% from 1.76 billion yuan in the previous period[19] Cash Flow - Operating cash flow decreased significantly by 90.59% to RMB 28.51 million due to reduced large project payments and increased operating expenses[9] - Investment cash flow improved by 57.74% to a net outflow of RMB 547.51 million, as there were no significant acquisition payments compared to the previous year[9] - Cash flow from operating activities decreased to 28.51 million yuan, down 90.59% from 303.08 million yuan in the previous period[20] - Cash flow from investing activities improved to -547.51 million yuan, compared to -1.30 billion yuan in the previous period[20] - Cash flow from financing activities decreased to 302.16 million yuan, down 43.34% from 533.08 million yuan in the previous period[20] - Cash and cash equivalents at the end of the period stood at 7.55 billion yuan, down 4.59% from 7.92 billion yuan in the previous period[21] - Cash paid for employee compensation increased to 788.73 million yuan, up 16.37% from 677.79 million yuan in the previous period[20] - Cash received from tax refunds increased to 3.13 million yuan, up 427.47% from 593,915.44 yuan in the previous period[20] Assets and Liabilities - The company's total assets grew by 2.64% to RMB 28.17 billion as of the end of Q1 2023[3] - Total assets at the end of the period amount to 28,172,127,699.99 yuan[14] - Total liabilities for the first quarter of 2023 were 4,853,582,844.27 RMB, compared to 4,765,479,654.95 RMB in the same period last year[15] - Total equity for the first quarter of 2023 was 23,318,544,855.72 RMB, up from 22,681,030,941.49 RMB in the same period last year[15] - Contract liabilities for the first quarter of 2023 were 870,900,929.39 RMB, down from 911,073,826.39 RMB in the same period last year[15] - Employee compensation payable for the first quarter of 2023 was 170,191,493.18 RMB, down from 292,868,161.24 RMB in the same period last year[15] - Taxes payable for the first quarter of 2023 were 180,537,915.05 RMB, down from 197,737,378.83 RMB in the same period last year[15] - Long-term loans for the first quarter of 2023 were 280,710,389.80 RMB, up from 244,641,137.61 RMB in the same period last year[15] - Lease liabilities for the first quarter of 2023 were 466,590,632.04 RMB, down from 488,975,554.75 RMB in the same period last year[15] - Monetary funds at the end of the period amount to 7,616,130,648.84 yuan[14] - Accounts receivable at the end of the period amount to 1,077,375,173.77 yuan[14] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 40,921[10] - Ye Xiaoping holds 20.32% of the shares, totaling 177,239,541 shares[10] - HKSCC NOMINEES LIMITED holds 14.11% of the shares, totaling 123,119,379 shares[10] - Hong Kong Securities Clearing Company Limited holds 9.26% of the shares, totaling 80,821,415 shares[10] - Cao Xiaochun holds 5.92% of the shares, totaling 51,661,774 shares[10] - Industrial and Commercial Bank of China - China Europe Medical Health Hybrid Securities Investment Fund holds 4.20% of the shares, totaling 36,652,574 shares[10] - TEMASEK FULLERTON ALPHA PTE LTD holds 2.23% of the shares, totaling 19,469,370 shares[10] Clinical Trial Services - Clinical trial technical service revenue declined slightly due to a reduction in multi-regional clinical trial business, particularly vaccine-related trials[6] - Clinical trial-related services and laboratory service revenue increased, driven by growth in data management, statistical analysis, and patient recruitment services[6] Financial Metrics - Fair value change gains increased by 40.98% to RMB 176.41 million, mainly due to gains from other non-current financial assets[8] - Financial expenses decreased by 47.37% to RMB -15.96 million, primarily due to reduced interest expenses[8] - The company's weighted average return on equity (ROE) slightly increased by 0.03 percentage points to 2.86%[3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3347） 2023年第一季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為杭州泰格醫藥科技股份有限公司（「本公司」，連同其子公司統稱「本集團」） 2023年財政年度第一季度報告。本公告及隨附的財務報表最初以中文編製，並以 中英文版本刊登。如中英文版本有任何歧義或衝突，概以中文版本為準。 謹請本公司股東及公眾投資者注意，隨附財務報表乃根據中國企業會計準則編製 且未經審計。 承董事會命 杭州泰格醫藥科技股份有限公司 葉小平 董事長 ...